2023-10 |
Efficacy of Limited Dose Modifications for Palbociclib-Related Grade 3 Neutropenia in Hormone Receptor-Positive Metastatic Breast Cancer |
Cancer Research and Treatment
|
2023-09 |
Copy number aberrations in circulating tumor DNA enables prognosis prediction and molecular characterization of breast cancer |
Journal of the National Cancer Institute
|
2023-07 |
Eflapegrastim versus Pegfilgrastim for Chemotherapy-Induced Neutropenia in Korean and Asian Patients with Early Breast Cancer: Results from the Two Phase III ADVANCE and RECOVER Studies |
CANCER RESEARCH AND TREATMENT
|
2023-06 |
Palbociclib (P) plus tamoxifen (TAM) ± goserelin in women with hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (ABC): Primary results of NCCH1607/PATHWAY, an Asian international double-blind randomized phase 3 trial. |
JOURNAL OF CLINICAL ONCOLOGY
|
2023-04 |
Integrative modeling of tumor genomes and epigenomes for enhanced cancer diagnosis by cell-free DNA |
Nature communications
|
2023-01 |
On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates |
Breast Cancer Research
|
2023-01 |
Outcomes of an Acute Palliative Care Unit at a Comprehensive Cancer Center in Korea |
Palliative Medicine Reports
|
2023-01 |
Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09) |
Cancer research and treatment
|
2023-01 |
Anaemia and pathologic complete response rate according to carboplatin dose in HER2+breast cancer treated with neoadjuvant TCHP |
CANCER MEDICINE
|
2022-08 |
Blood Test for Breast Cancer Screening through the Detection of Tumor-Associated Circulating Transcripts |
International Journal of Molecular Sciences
|
2022-04 |
Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer |
Breast
|
2021-10 |
Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations |
INVESTIGATIONAL NEW DRUGS
|
2021-07 |
Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL) |
CANCER RESEARCH AND TREATMENT
|
2021-07 |
Risk of Lymphedema Following Contemporary Treatment for Breast Cancer: An Analysis of 7617 Consecutive Patients From a Multidisciplinary Perspective |
ANNALS OF SURGERY
|
2021-06 |
Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer |
FRONTIERS IN ONCOLOGY
|
2021-04 |
Genomic landscape of extraordinary responses in metastatic breast cancer |
COMMUNICATIONS BIOLOGY
|
2021-02 |
Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study |
EUROPEAN JOURNAL OF CANCER
|
2021-01 |
Use of bevacizumab before or after radiotherapy increases the risk of fistula formation in patients with cervical cancer |
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
|
2020-11 |
Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10) |
Cancers
|
2020-08 |
Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer |
BREAST CANCER RESEARCH AND TREATMENT
|
2020-08 |
Local Treatment in Addition to Endocrine Therapy in Hormone Receptor-Positive and HER2-Negative Oligometastatic Breast Cancer Patients: A Retrospective Multicenter Analysis |
BREAST CARE
|
2020-07 |
Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting |
CANCER RESEARCH AND TREATMENT
|
2020-06 |
Cardiotoxicity evaluation using magnetic resonance imaging in breast Cancer patients (CareBest): study protocol for a prospective trial |
BMC CARDIOVASCULAR DISORDERS
|
2020-03 |
Changes in taste and food preferences in breast cancer patients receiving chemotherapy: a pilot study |
SUPPORTIVE CARE IN CANCER
|
2020-02 |
Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older |
BREAST CANCER RESEARCH AND TREATMENT
|
2019-09 |
Involved-field radiation therapy for selected cases of recurrent ovarian cancer |
JOURNAL OF GYNECOLOGIC ONCOLOGY
|
2019-09 |
Effect of primary tumor resection on overall survival in patients with stage IV breast cancer. |
BREAST JOURNAL
|
2019-04 |
A Phase II Study to Evaluate the Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients Receiving Dose-Dense Doxorubicin/Cyclophosphamide. |
CANCER RESEARCH AND TREATMENT
|
2018-08 |
Comparative clinicopathological and cytomorphological analyses of peritoneal carcinomatosis associated with metastatic breast carcinoma and primary peritoneal/ovarian carcinoma in patients with a history of breast carcinoma |
VIRCHOWS ARCHIV
|
2018-07 |
Feasibility of Charcoal Tattooing of Cytology-Proven Metastatic Axillary Lymph Node at Diagnosis and Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients |
CANCER RESEARCH AND TREATMENT
|
2018-06 |
External validation of IBTR! 2.0 nomogram for prediction of ipsilateral breast tumor recurrence |
Radiation Oncology Journal
|
2017-05 |
Next-generation sequencing of BRCA1/2 in breast cancer patients: potential effects on clinical decision-making using rapid, high-accuracy genetic results |
ANNALS OF SURGICAL TREATMENT AND RESEARCH
|